臨床研究等提出・公開システム

Date of registration	Aug. 04, 2026
Last modified on	Aug. 26, 2026
Trial ID	jRCT1040260037

Scientific Title	Elucidation of the potential roles of PAPPis to enhance the effects of immune checkpoint inhibitors in endometrial cancer using patient-derived organoids
Public Title	Elucidation of the mechanisms by which PARP inhibitors enhance the efficacy of immune checkpoint inhibitors

Contact for Scientific Queries	Name	Abiko Kaoru
	Affiliation	Kanazawa University
	Address	13-1, Takaramachi, Kanazawa city
	Telephone	+81-762652425
	E-mail	kaoruvc@gmail.com
Contact for Public Queries	Name	IIZUKA TAKASHI
	Affiliation	Kanazawa University
	Address	13-1, Takaramachi, Kanazawa city
	Telephone	+81-762652425
	E-mail	zukatti713@gmail.com

Recruitment status	Pending

Anticipated date of first enrollment		Aug. 04, 2026
Target sample size		20
Study Type		Observational
Study Design	allocation	single arm study
	masking	open(masking not used)
	control	uncontrolled control
	assignment	parallel assignment
	purpose	basic science
Key inclusion & exclusion criteria	Inclusion Criteria	1. Patients diagnosed with endometrial cancer who undergo surgical treatment. 2. Patients aged 20 years or older and 90 years or younger at the time of consent. 3. Patients who have provided written informed consent to participate in the study.
	Exclusion Criteria	Patients deemed unsuitable for inclusion in the study at the discretion of the physician.
	Age Minimum	20age old over
	Age Maximum	90age old under
	Gender	Female
Health Condition(s) or Problem(s) Studied		Uterine endometrial cancer
Health Condition(s) Keyword		Endometrial cancer, PARP inhibitors, immune checkpoint inhibitors, tumor microenvironment
Primary Outcome(s)		1. Analysis of the viability, intracellular nucleic acid levels, and gene expression changes in endometrial cancer organoids treated with PARP inhibitors. 2. Evaluation of gene expression changes in organoids and T cells following co-culture with T cells and combined treatment with immune checkpoint inhibitors and PARP inhibitors.
Secondary Outcome(s)		none

Primary Sponsor	AstraZeneca K.K.

Source of Monetary Support / Secondary Sponsor	AstraZeneca K.K.
Secondary Sponsor

Secondary Sponsor

Name of Certified Review Board	Medical Ethics Committee of Kanazawa Universit
Address	13-1, Takaramachi, Kanazawa city, Ishikawa
Telephone	+81-76-265-2048
E-Mail	rinri@adm.kanazawa-u.ac.jp
Approval Status	Approval

Plan to share IPD	No

Countries of Recruitment（Except Japan）	none

History of Changes

No	Publication date
2	Aug. 26, 2026	(this page)	Changes
1	Aug. 04, 2026	Detail

List of change history